OakChart

Arrowhead Pharmaceuticals Inc

ARWRHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:00 AM ET

48.74-0.26 (-0.54%)
2026-11-11 16:00 CET
Market cap
6,921.45 USD m
Revenue, TTM
669.50 USD m
Net income, TTM
-319.95 USD m
Free cash flow, TTM
-75.11 USD m
EPS diluted, TTM
-2.24
P/E
-
Compare

Price

ARWR against its 20, 50 and 200-day averages
2050200missearnings
60.0080.009.4M18.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARWRclose 48.7420-day 57.3950-day 64.85200-day 71.2848.74

49.0% under 95.49 on 22 Jul 2026. Last 15 sessions, 33.5% high to low

Profile

ARWR
52-week range, 20% of the way up
37.0695.49

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

IndexRUI
Employees711
IPODec 16, 1993
Beta1.39
ATR, 14d3.05
Rel volume0.91
Short float8.71%
Insider own5.87%
Inst own82.93%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap6.88B
Enterprise Value6.66B
Income-319.95M
Sales669.50M
Book/sh3.30
Cash/sh11.34
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees711
IPODec 16, 1993

Ratios

P/E-
Forward P/E-
PEG-
P/S10.28
P/B14.78
P/C4.30
P/FCF-
EV/EBITDA-
EV/Sales9.95
Quick Ratio5.90
Current Ratio5.90
Debt/Eq2.96
LT Debt/Eq2.86
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.24
EPS next Y-4.86
EPS next Q-1.52
EPS this Y-35135.10%
EPS next Y-37.82%
EPS next 5Y-
EPS past 3/5Y80.60% 57.10%
Sales past 3/5Y50.52% 56.63%
EPS Y/Y TTM-80.39%
Sales Y/Y TTM16.85%
EPS Q/Q-7.51%
Sales Q/Q171.02%
EarningsNov 12 AMC
EPS/Sales Surpr.-6.52% 70.36%

Ownership

Insider Own5.87%
Insider Trans-0.20%
Inst Own82.93%
Inst Trans-2.14%
ROA-18.32%
ROE-64.78%
ROIC-17.81%
Gross Margin96.15%
Oper. Margin-33.82%
Profit Margin-47.79%
SMA20-15.08%
SMA50-24.85%
SMA200-31.63%
Trades-

Technical

Shs Outstand141.13M
Shs Float132.97M
Short Float8.71%
Short Ratio6.26
Short Interest11.58M
52W High95.49 -48.96%
52W Low37.06 31.50%
Volatility7.37% 4.67%
ATR (14)3.05
RSI (14)24.75
Beta1.39
Rel Volume0.91
Avg Volume1.85M
Volume206,567

Performance

Perf Week-20.95%
Perf Month-16.16%
Perf Quarter-43.06%
Perf Half Y-37.42%
Perf YTD-26.59%
Perf Year17.43%
Perf 3Y80.77%
Perf 5Y-35.69%
Perf 10Y1065.91%
Recom1.12
Target Price107.92
Prev Close49.00
Price48.74
Change %-0.54%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 15, 2026ResumedUUBSBuy$109+123.7%
Sep 24, 2026ResumedGGoldmanNeutral$74+51.8%
Sep 08, 2026InitiatedCCitigroupBuy$108+121.6%
Jul 14, 2026InitiatedSStifelBuy$98+101.1%
May 01, 2026InitiatedJJP MorganOverweight$88+80.6%
Apr 21, 2026UpgradeMMorgan StanleyEqual-Weight → Overweight$100+105.2%
Jun 05, 2024InitiatedGGoldmanNeutral$31-36.4%
Dec 04, 2023InitiatedBBofA SecuritiesBuy$29-40.5%
Sep 19, 2023InitiatedCCitigroupNeutral$33-32.3%
Jul 21, 2023InitiatedTTD CowenOutperform

Peers

Mkt cap
TickerCompanyMkt cap
ALNYAlnylam Pharmaceuticals Inc20.62B
IONSIonis Pharmaceuticals Inc4.79B
SLNSilence Therapeutics Plc ADR1.23B
WVEWave Life Sciences Inc680.44M
DYNDyne Therapeutics Inc3.39B
CRSPCRISPR Therapeutics AG4.35B
ABUSArbutus Biopharma Corp736.95M
SRPTSarepta Therapeutics Inc1.76B
MDGLMadrigal Pharmaceuticals Inc10.16B
NTLAIntellia Therapeutics Inc1.57B

Insider trading

latest 14 of 43
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
OLUKOTUN ADEOYE YDirectorAug 18 '26Sale86.962,000173,92031,600Aug 20 05:25 PM
PERRY MICHAEL SDirectorAug 18 '26Sale87.3011,6001,012,680111,459Aug 20 05:22 PM
Adeoye OlukotunDirectorAug 18 '26Proposed Sale86.942,000173,876Aug 18 05:31 PM
Michael PerryDirectorAug 18 '26Proposed Sale87.2611,6001,012,172Aug 18 05:24 PM
Lu HongboDirectorMay 12 '26Sale76.882,970228,33452,012May 14 07:05 PM
Hongbo LuOfficerMay 12 '26Proposed Sale76.872,970228,299May 12 04:35 PM
Apel Daniel JosephChief Financial OfficerApr 22 '26Sale71.3513,095934,285162,905Apr 24 06:44 PM
Hamilton James CChief Medical OfficerApr 23 '26Sale75.0010,000750,000226,958Apr 24 06:38 PM
James HamiltonOfficerApr 23 '26Proposed Sale75.0010,000749,998Apr 23 04:44 PM
Daniel ApelOfficerApr 22 '26Proposed Sale71.3413,095934,206Apr 22 05:16 PM
Hamilton James CChief Medical OfficerMar 05 '26Sale64.1910,000641,900236,958Mar 09 07:00 PM
James HamiltonOfficerMar 05 '26Proposed Sale64.1910,000641,870Mar 05 04:49 PM
O'Brien PatrickCOOJan 05 '26Sale63.1149,4933,123,349474,908Jan 05 09:50 PM
Hamilton James CChief Medical OfficerJan 05 '26Sale63.1140,1642,534,661171,958Jan 05 09:41 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
XMMOInvesco S&P MidCap Momentum ETFAUM: 6.37B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
IBBiShares Biotechnology ETFAUM: 11.36B
IJKiShares S&P Mid-Cap 400 Growth ETFAUM: 10.46B

News

latest 14 of 206
  • PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure. (Barrons.com)
  • Mid-cap biotech catalysts: FDA dates, earnings, and pipeline data to watch (Investing.com) -15.34%
  • Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
  • Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates (Business Wire)
  • Arrowhead Must Show Redemplo Traction And SHTG Filing Progress After 32% Slide (Earnings Whispers) -6.80%
  • Loading…
  • Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity (Business Wire)
  • Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results (Business Wire)
  • Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026 (Business Wire)
  • Arrowhead gains UK marketing authorisation for Redemplo (Pharmaceutical Technology)
  • Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO (Plozasiran) as a New Treatment Option to Reduce Triglycerides (Business Wire)
  • Arrowheads Alzheimers disease drug reduces tau in Phase I/IIa trial (Clinical Trials Arena)
  • Arrowheads Alzheimers Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial Heres What Investors Need To Know (Stocktwits)
  • Arrowhead jumps as breakthrough Alzheimers drug clears brain barrier (Investing.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q42026-11-12--1.518--61.1815
2026Q32026-08-04-1.360-1.277-1.35875.2544.1712
2026Q22026-05-07-0.930-1.095-0.93273.7473.8411
2026Q12026-02-050.2200.0370.219264.03213.9411
2025Q42025-11-25-0.110-0.112-0.175256.47175.3212
2025Q32025-08-07-1.260-0.952-1.26027.7746.8314
2025Q22025-05-122.750-0.1872.755542.71125.413
2025Q12025-02-10-1.390-0.476-1.3862.5069.0513
2024Q42024-11-26-1.360-1.120-1.3710.0055.0713
2024Q32024-08-08-1.380-0.529-1.3750.0052.8714
2024Q22024-05-09-1.020-0.472-1.0160.0041.9714
2024Q12024-02-06-1.240-0.801-1.2373.5533.8711
2023Q42023-11-29-1.020-0.609-1.02216.1044.6314
2023Q32023-08-07-0.960-0.569-0.96215.8345.4212
2023Q22023-05-020.450-0.6180.450146.2745.4812
2023Q12023-02-06-0.3900.370-0.39062.55162.5212

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.6900.7570.689168.8165.95
2020FY-0.840-0.254-0.84087.99132.14
2021FY-1.360-0.693-1.358138.29134.59
2022FY-1.670-1.379-1.670243.23255.58
2023FY-1.920-1.496-1.923240.74263.61
2024FY-5.000-4.697-5.0053.5562.14
2025FY-0.0100.088-0.010829.45764.56
2026FY--3.524--464.24
2027FY--4.856--330.13
2028FY--2.810--666.07
2029FY--0.736--1,148
2030FY-4.406--2,044

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-11140061.184.50178
2026Q4S2026-10-19140161.184.50178
2026Q4S2026-10-13143561.184.50178
2026Q4S2026-09-23133559.194.50178
2026Q4S2026-09-08123559.434.50178
2026Q4S2026-08-28113560.314.50178
2026Q4S2026-08-05113471.764.50178
2026Q4S2026-08-04110372.734.50177.69
2026Q4S2026-07-29110372.734.50177.69
2026Q4S2026-07-25110276.624.50177.69
2026Q4S2026-07-22111276.624.50177.69
2026Q4S2026-07-21113476.624.50177.69
2026Q4S2026-07-16103468.684.50177.69
2026Q4S2026-07-10103468.924.50177.69

Estimate history

EPS, annual-0.465-0.6510.689-0.84-1.358-1.67-1.923-5.005-0.012-2.2431
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.375-1.371-1.3862.755-1.26-0.1750.219-0.932-1.355
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual31.40816.142168.79687.992138.287243.231240.7353.551829.448669.5
Period201720182019202020212022202320242025TTM
Sales, quarterly002.5542.70927.767256.472264.03373.73775.253
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual74.78688.50595.506102.376104.327105.96107.312124.376135.702141.135
Period201720182019202020212022202320242025MRQ
Shares, quarterly124.227124.376125.572138.062138.144135.702137.391140.571141.135
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue669.50829.453.55240.74243.23138.2987.99168.8016.14
Cost of Goods Sold Incl. D&A25.8023.9318.5912.4910.42----
Gross Profit643.69805.52-15.04228.24232.81----
Selling, General and Administrative Excl. Other870.13707.17586.04433.24411.32279.06175.21103.1767.38
Research and Development699.56585.26489.22342.31288.50198.98123.5476.6348.30
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-226.4498.35-601.08-205.00-178.51-149.04-93.1661.19-55.94
Interest Expense92.6189.3632.3518.330.000.000.00--
Unusual Expense0.000.000.000.000.000.000.000.00-0.43
Net Income Before Taxes-252.0851.53-612.46-206.49-172.71-140.85-84.5568.15-54.45
Income Taxes20.0521.42-2.772.783.790.000.000.170.00
Consolidated Net Income-272.1230.11-609.69-209.28-176.49-140.85-84.5567.97-54.45
Net Income From Continuing Operations-319.95-1.63-599.49-205.28-176.06-140.85-84.5567.97-54.45
Net Income-319.95-1.63-599.49-205.28-176.06-140.85-84.5567.97-54.45
EPS (Recurring)-2.23-0.01-5.00-1.92-1.67-1.36-0.840.69-0.65
EPS (Basic, Before Extraordinaries)-2.24-0.01-5.00-1.92-1.67-1.36-0.840.72-0.65
EPS (Diluted)-2.24-0.01-5.00-1.92-1.67-1.36-0.840.69-0.65
EBITDA-200.63122.27-582.49-192.51-168.09-140.77-87.2265.63-51.24
Non-Operating Income (Expense)66.9742.5520.9716.845.808.198.616.961.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense57.8750.0658.4361.7295.5155.9731.679.056.68
Price To Earnings Ratio-------40.54-
Price To Sales Ratio17.465.56653.4011.9214.3346.8449.2916.4699.33
Gross Margin96.1597.12-423.6694.8195.72----
Operating Margin-33.8211.86-16,927.06-85.16-73.39-107.77-105.8736.25-346.52
Net Margin-47.79-0.20-16,882.37-85.27-72.39-101.85-96.0940.27-337.32
Shares Outstanding141.13135.70124.38107.31105.96104.33102.3895.5188.51
Market Capitalization6,921.456,921.452,407.982,880.283,498.316,508.894,404.692,685.581,687.40

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue75.2573.74264.03256.4727.77542.712.500.00
Cost of Goods Sold Incl. D&A6.666.376.396.396.226.085.245.03
Gross Profit68.5967.37257.64250.0921.54536.62-2.73-5.03
Selling, General and Administrative Excl. Other238.69208.63216.83205.98187.09155.42158.68157.18
Research and Development192.06167.38171.32168.80156.65127.53132.28131.39
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-170.09-141.2640.8144.11-165.55381.20-161.41-162.20
Interest Expense24.5623.8522.5021.6924.3821.6421.6514.65
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-178.91-137.5628.2736.12-179.09369.62-175.12-172.80
Income Taxes0.010.010.0320.00-0.441.750.100.55
Consolidated Net Income-178.92-137.5728.2416.12-178.65367.86-175.22-173.34
Net Income From Continuing Operations-194.28-132.7330.81-23.75-175.24370.44-173.09-170.54
Net Income-194.28-132.7330.81-23.75-175.24370.44-173.09-170.54
EPS (Recurring)-1.36-0.930.22-0.18-1.262.75-1.39-1.37
EPS (Basic, Before Extraordinaries)-1.35-0.930.22-0.17-1.262.78-1.39-1.37
EPS (Diluted)-1.35-0.930.22-0.17-1.262.75-1.39-1.37
EBITDA-163.43-134.8947.2050.49-159.33387.29-156.18-157.18
Non-Operating Income (Expense)15.7527.549.9713.7110.8410.057.944.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.8313.0915.4817.479.4711.9111.2015.38
Price To Earnings Ratio-40.76------
Price To Sales Ratio17.4614.368.565.643.833.14938.86678.45
Gross Margin91.1591.3697.5897.5177.5998.88-109.40-
Operating Margin-226.03-191.5715.4617.20-596.2170.24-6,456.48-
Net Margin-258.17-180.0111.67-9.26-631.1168.26-6,923.40-
Shares Outstanding141.13140.57137.39135.70138.14138.06125.57124.38
Market Capitalization6,921.458,780.019,016.434,768.522,181.981,749.422,339.362,407.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments919.37680.96403.63376.40367.79315.49258.7076.5365.61
Short Term Receivables6.820.000.001.4110.260.850.660.330.07
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets24.4514.5115.8927.496.556.035.881.912.23
Total Current Assets950.64695.47419.52405.30384.60322.37265.2578.7767.90
Net Property, Plant & Equipment426.41431.29335.56168.5966.0247.0223.2113.9415.51
Total Investments and Advances0.000.000.00105.87245.59137.4944.180.000.00
Intangible Assets6.868.5610.2611.9613.6615.3617.0618.7620.46
Deferred Tax Assets65.14--------
Other Assets1.394.480.210.220.270.270.140.140.14
Total Assets1,450.441,139.80765.55691.94710.15522.50349.85111.61104.02
Short Term Debt Incl. Current Port. of LT Debt47.296.3410.562.782.251.090.000.220.21
Accounts Payable17.6711.3935.872.879.466.837.652.814.08
Income Tax Payable20.80--------
Other Current Liabilities109.7285.4459.03133.21134.8332.7689.429.3414.42
Total Current Liabilities195.49103.17105.46138.85146.5440.6897.0712.3618.70
Long Term Debt686.39845.57372.9378.8023.3020.040.002.102.33
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities65.14--------
Other Liabilities0.000.000.0055.95131.500.008.741.902.13
Total Liabilities947.02948.74478.39273.60301.3360.72105.8116.3723.16
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity466.05185.44271.34398.52408.82461.78244.5995.8081.42
Total Shareholders Equity466.05185.44271.34398.52408.82461.78244.5995.8081.42
Accumulated Minority Interest37.365.6215.8219.820.000.00-0.56-0.56-0.56
Total Equity503.42191.06287.16418.34408.82461.78244.0495.2480.87
Total Liabilities & Stockholders Equity1,450.441,139.80765.55691.94710.15522.50349.85111.61104.02
Book Value Per Share3.431.492.533.763.924.512.561.081.09
Tangible Book Value Per Share3.381.422.433.653.794.362.380.870.82
Full-Time Employees71160952539732923213411693
Price to Book Ratio14.867.287.898.7915.939.5511.0016.463.59
Return on Assets-0.13-62.93-28.17-25.11-22.85-19.3929.46-50.50-29.61
Return on Equity-0.50-262.48-61.29-43.62-32.36-23.9439.94-61.45-38.85
Return on Invested Capital-0.14-58.15-31.86-36.89-32.59-17.5527.79-55.62-41.05
Quick Ratio4.866.743.982.922.627.922.736.373.63
Current Ratio4.866.743.982.922.627.922.736.373.63

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-272.1330.11-609.69-209.28-176.49-140.85-84.5567.97-54.45
Depreciation25.8023.9318.5912.4910.428.275.944.444.70
Other Funds (Non Cash)144.78143.75103.1694.44128.2476.9443.9113.468.41
Funds from Operations-101.55197.79-487.94-102.34-37.84-55.64-34.7085.88-41.35
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital42.49-18.2325.09-51.55-98.29226.87-60.6987.16-5.88
Cash from Operating Activities-59.05179.55-462.85-153.89-136.13171.22-95.39173.03-47.22
Capital Expenditures-16.06-22.67-141.47-176.74-52.78-23.57-11.95-12.00-1.42
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-785.67-106.63-278.6080.5847.36-118.11-228.83-35.74-6.01
Purchase of Investments-1,160.36-796.26-720.95-246.14-223.39-240.70-278.96-90.27-52.08
Sale Or Maturity of Investments374.69689.63442.34326.72270.75122.5950.1454.5246.07
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-801.72-129.29-420.07-96.16-5.42-141.68-240.78-47.75-7.43
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock303.95270.37431.653.055.1911.30257.9568.8060.16
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock303.95270.37431.653.055.1911.30257.9568.8060.16
Proceedsfrom Stock Options265.68241.39429.260.000.000.00250.4860.5256.53
Issuance or Reduction of Debt, Net566.55-196.37438.87250.000.000.000.00-2.42-0.21
Change in Long Term Debt566.55-196.37438.87250.000.000.000.00-2.42-0.21
Issuance of Long Term Debt684.455.26438.87250.000.000.000.000.000.00
Reduction of Long Term Debt-117.89-201.620.000.000.000.000.00-2.42-0.21
Net Financing Active Other Cash Flow-86.310.000.000.0060.000.000.000.000.00
Other Financing Activities Uses-86.310.000.000.000.000.000.000.000.00
Cash from Financing Activities784.1974.01870.52253.0565.1911.30257.9566.3859.95
Exchange Rate Effect1.56-0.404.20------
Net Change in Cash-75.03123.86-8.213.01-76.3640.85-78.22191.675.29
Free Cash Flow-75.11156.89-604.32-330.63-188.91147.66-107.34161.03-48.64
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-29.41---43.86-17.26-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,601.961,784.09916.61919.37900.371,097.41
Short Term Receivables18.7915.69218.876.829.702.37
Inventories0.000.000.000.000.000.00
Other Current Assets50.6639.9838.9124.4536.8535.45
Total Current Assets1,671.411,839.751,174.39950.64946.921,135.22
Net Property, Plant & Equipment428.97417.62421.94426.41425.05429.25
Total Investments and Advances2.204.700.000.000.000.00
Intangible Assets5.596.016.446.867.297.71
Deferred Tax Assets---65.14--
Other Assets3.850.191.411.391.351.31
Total Assets2,112.012,268.261,604.181,450.441,380.611,573.50
Short Term Debt Incl. Current Port. of LT Debt45.3247.7747.5347.2947.0171.78
Accounts Payable27.7830.7532.9417.6733.059.98
Income Tax Payable0.000.0010.8920.80--
Other Current Liabilities210.25216.70256.07109.72114.47138.78
Total Current Liabilities283.35295.22347.43195.49194.53220.54
Long Term Debt1,330.881,325.51640.23686.39666.28668.73
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---65.14--
Other Liabilities31.7448.6253.830.000.000.00
Total Liabilities1,645.971,669.351,041.48947.02860.81889.27
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity465.53613.98568.42466.05522.31683.32
Total Shareholders Equity465.53613.98568.42466.05522.31683.32
Accumulated Minority Interest0.51-15.06-5.7237.36-2.510.90
Total Equity466.04598.92562.70503.42519.81684.23
Total Liabilities & Stockholders Equity2,112.012,268.261,604.181,450.441,380.611,573.50
Book Value Per Share3.304.374.143.433.784.95
Tangible Book Value Per Share3.264.324.093.383.734.89
Full-Time Employees---711--
Price to Book Ratio14.8615.1519.339.123.1930.42
Return on Assets-18.32-15.6715.45-0.13-13.11-11.39
Return on Equity-64.78-46.3965.14-0.50-34.80-24.67
Return on Invested Capital-10.81-6.842.55-2.06-14.7427.40
Quick Ratio5.906.233.384.864.875.15
Current Ratio5.906.233.384.864.875.15

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-178.92-137.5728.2416.12-178.65367.86
Depreciation6.666.376.396.396.226.08
Other Funds (Non Cash)40.3027.4940.6436.3440.6740.58
Funds from Operations-131.96-103.7175.2758.85-131.76414.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-45.51188.15-61.79-38.36-17.9645.52
Cash from Operating Activities-177.4784.4413.4820.49-149.72460.05
Capital Expenditures-3.85-2.56-2.15-7.49-2.36-5.30
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments47.54-891.72-21.5980.11143.75-414.92
Purchase of Investments-77.14-924.64-136.93-21.64-96.72-644.14
Sale Or Maturity of Investments124.6732.93115.34101.75240.48229.23
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities43.68-894.28-23.7472.62141.39-420.21
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock29.86221.6551.930.510.22244.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock29.86221.6551.930.510.22244.01
Proceedsfrom Stock Options27.24216.6046.83-25.000.00266.39
Issuance or Reduction of Debt, Net-33.38663.46-66.683.16-47.90-151.62
Change in Long Term Debt-33.38663.46-66.683.16-47.90-151.62
Issuance of Long Term Debt0.00681.280.003.162.100.00
Reduction of Long Term Debt-33.38-17.83-66.680.00-50.00-151.62
Net Financing Active Other Cash Flow3.08-89.390.000.000.000.00
Other Financing Activities Uses3.08-89.390.000.000.000.00
Cash from Financing Activities-0.45795.72-14.753.67-47.6892.38
Exchange Rate Effect0.481.000.11-0.020.09-0.40
Net Change in Cash-133.76-13.13-24.9196.75-55.92131.82
Free Cash Flow-181.3281.8811.3313.00-152.08454.76
Price to Free Cash Flow--28.5729.83-372.79

Revenue breakdown

Pharmaceutical Preparations2024: 3.55M 2025: 829.45M
United States2024: 3.55M 2025: 829.45M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.71%11.6M133.0M1.72M
2026-10-158.24%11.0M133.0M1.93M
2026-09-308.09%10.8M133.0M1.92M
2026-09-156.97%9.3M133.0M2.08M
2026-08-317.09%9.4M132.9M2.02M
2026-08-146.93%9.2M132.9M2.10M
2026-07-317.27%9.7M132.8M2.21M
2026-07-157.27%9.6M132.5M2.10M
2026-06-306.37%8.4M132.4M2.03M
2026-06-158.87%11.7M132.3M1.83M
2026-05-299.37%12.4M132.3M2.03M
2026-05-159.77%12.9M132.3M2.11M
2026-04-309.81%12.9M131.9M2.63M
2026-04-159.16%12.0M131.1M2.65M
2026-03-319.94%13.0M130.8M2.99M
2026-03-138.74%11.4M130.8M2.87M
2026-02-278.52%11.1M130.8M3.02M
2026-02-138.27%10.8M130.8M3.21M
2026-01-308.56%11.2M130.2M2.66M
2026-01-158.57%10.8M125.9M2.61M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call25.0022.1025.400.004.1440.000.000.934-0.1870.010
call30.0017.4020.400.003.2270.000.000.916-0.1770.012
call35.0012.4015.600.002.4380.000.000.889-0.1630.015
call40.007.4010.908.151.95825.000.000.847-0.1430.018
call42.505.508.506.401.6708.000.000.760-0.1960.024
call45.003.406.5014.501.5956.000.000.703-0.1790.027
call47.501.854.103.141.1084.000.000.597-0.2060.030
call50.001.402.501.910.9636010.000.489-0.1940.031
call52.500.151.751.601.01016.000.000.369-0.1720.029
call55.000.402.800.851.2781000.000.308-0.1910.027
call57.500.102.300.551.4683120.000.280-0.2110.026
call60.000.052.050.071.6532790.000.258-0.2280.025
call62.500.051.800.251.8511,6130.000.240-0.2440.024
call65.000.000.400.301.2161,2650.000.095-0.0840.014
call67.500.050.950.481.41232.000.000.087-0.0950.012
call70.000.001.050.151.5261,2390.000.082-0.0980.012
call72.500.001.300.761.61615.000.000.078-0.1010.011
call75.000.001.250.101.7185210.000.075-0.1030.011
call80.000.001.150.101.9241,7280.000.069-0.1080.010
call85.000.001.150.202.09811.000.000.064-0.1120.010
call90.000.001.100.052.2581260.000.061-0.1150.009
call95.000.000.950.752.40666.000.000.058-0.1180.009
call1000.001.300.052.52882.000.000.056-0.1210.009
call1050.001.050.212.6741.000.000.054-0.1230.008
call1100.002.150.002.7950.000.000.052-0.1250.008
call1150.002.150.002.9100.000.000.050-0.1270.008
put25.000.000.950.003.4070.000.00-0.066-0.1840.010
put30.000.001.700.002.6360.000.00-0.085-0.1730.012
put35.000.000.950.001.9911.000.00-0.111-0.1590.015
put40.000.000.950.831.3721.000.00-0.156-0.1370.018
put42.500.002.900.831.4852.000.00-0.237-0.1930.024
put45.000.001.801.101.1535.000.00-0.297-0.1740.027
put47.500.253.301.851.2823260.00-0.410-0.1990.030
put50.001.504.903.401.3632150.00-0.523-0.1870.031
put52.503.206.401.211.3231850.00-0.642-0.1650.029
put55.005.308.406.791.39785.000.00-0.693-0.1860.027
put57.507.6010.5010.251.4591520.00-0.722-0.2060.026
put60.0010.0013.0010.801.6481,6490.00-0.744-0.2230.025
put62.5012.4015.5014.101.8201,0290.00-0.761-0.2370.024
put65.0014.8017.5015.541.7485960.00-0.906-0.0840.013
put67.5017.3020.5020.432.1298.000.00-0.913-0.0880.012
put70.0019.8023.0022.102.2692480.00-0.918-0.0900.012
put72.5022.3026.108.902.6703.000.00-0.922-0.0930.011
put75.0024.8028.3027.602.66557.000.00-0.925-0.0950.011
put80.0029.7033.4033.002.94854.000.00-0.931-0.0990.010
put85.0034.7038.6024.803.25833.000.00-0.936-0.1020.010
put90.0039.7043.500.003.4110.000.00-0.939-0.1050.009
put95.0044.7048.000.003.3380.000.00-0.942-0.1070.009
put10049.7053.000.003.5050.000.00-0.944-0.1100.009
put10554.7058.100.003.7160.000.00-0.946-0.1110.008
put11059.7063.000.003.8060.000.00-0.948-0.1130.008
put11564.7068.200.004.0570.000.00-0.950-0.1150.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-048-KCurrent report2026-11-04SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-27SCHEDULE 13G/ASEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-173Initial statement of beneficial ownership of securities2026-06-15SEC
2026-06-168-KCurrent report2026-06-12SEC
2026-05-19144/ASEC
2026-05-19144/ASEC
2026-05-19144/ASEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-12144Filing for proposed sale of securities under Rule 144.SEC
2026-05-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-06SCHEDULE 13GSEC
2026-04-29SCHEDULE 13GSEC
2026-04-28SCHEDULE 13GSEC
2026-04-24SCHEDULE 13G/ASEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-23SEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-22SEC
2026-04-23144Filing for proposed sale of securities under Rule 144.SEC
2026-04-22144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08001.19M2
2026-070000
2026-060000
2026-0500228.33K1
2026-04001.68M2
2026-0300641.90K1
2026-020000
2026-01006.53M3
2025-120026.58M11
2025-1100493.41K1

Institutional holders

Manager% owned
BlackRock, Inc.10.53%
Avoro Capital Advisors LLC8.06%
FMR LLC6.62%
VANGUARD PORTFOLIO MANAGEMENT LLC4.51%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
STATE STREET CORP4.04%
STATE OF WISCONSIN INVESTMENT BOARD2.89%
NORGES BANK2.77%
Invesco Ltd.2.76%
GEODE CAPITAL MANAGEMENT, LLC2.45%

Funds

Fund% owned
NYLIM MacKay Convertible Fund11.34%
NYLIM VP MacKay Convertible Portfolio4.86%
iShares Core S&P Mid-Cap ETF3.42%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.01%
Fidelity Convertible Securities Fund2.93%
VANGUARD SMALL-CAP INDEX FUND2.18%
Fidelity Growth Company Fund1.84%
Invesco Convertible Securities Fund1.42%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.26%
Invesco S&P MidCap Momentum ETF1.23%

OakChart. ARWR. Cached 15 minutes.